Tivozanib (BioDeep_00000858592)
代谢物信息卡片
Tivozanib (AV-951)
化学式: C22H19ClN4O5 (454.1044)
中文名称: 替沃扎尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
InChI: InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EK - Vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:91327
- KEGGdrug: D09683
- PubChem: 9911830
- DrugBank: DB11800
- ChEMBL: CHEMBL1289494
- CAS: 475108-18-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Hollis Viray, David F McDermott, David J Einstein. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Expert review of anticancer therapy.
2022 Jul; 22(7):695-702. doi:
10.1080/14737140.2022.2088515. [PMID: 35698870] - Laura Caquelin, Mohamed Gewily, Wendy Mottais, Chloé Tebaldi, Bruno Laviolle, Florian Naudet, Clara Locher. Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
BMC cancer.
2022 Apr; 22(1):381. doi:
10.1186/s12885-022-09475-7. [PMID: 35397511] - Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H Fiero, Miao Zhao, Eias Zahalka, Tiffany K Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B Goldberg, Shenghui Tang, Paul G Kluetz, Richard Pazdur, Amna Ibrahim, Julia A Beaver, Laleh Amiri-Kordestani. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 02; 28(3):441-445. doi:
10.1158/1078-0432.ccr-21-2334. [PMID: 34417198] - Michael Szarek, Michael N Needle, Brian I Rini, Sumanta K Pal, David F McDermott, Michael B Atkins, Thomas E Hutson, Bernard J Escudier. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Clinical genitourinary cancer.
2021 10; 19(5):468.e1-468.e5. doi:
10.1016/j.clgc.2021.03.018. [PMID: 33980467] - W-Y Chen, Z-X Fang, X-D Lv, Q-H Zhou, M Yao, M Deng. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.
European review for medical and pharmacological sciences.
2021 04; 25(7):3122-3131. doi:
10.26355/eurrev_202104_25567. [PMID: 33877681] - L Meza, P G Bergerot, N Agarwal, S K Pal. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021 01; 32(1):12-14. doi:
10.1016/j.annonc.2020.10.481. [PMID: 33121996] - L Albiges, P Barthélémy, M Gross-Goupil, S Negrier, M N Needle, B Escudier. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021 01; 32(1):97-102. doi:
10.1016/j.annonc.2020.09.021. [PMID: 33010459] - Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, Francesco Massari, Alessandra Bearz, Lucia Fratino, Michele Milella, Maria Bassanelli, Paola Ermacora, Davide Bimbatti, Elena Verzoni, Mimma Rizzo, Camillo Porta. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology.
2021; 99(12):747-755. doi:
10.1159/000515951. [PMID: 34583356] - Sumanta K Pal, Bernard J Escudier, Michael B Atkins, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael N Needle, Daniel Powers, David F McDermott, Brian I Rini. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
European urology.
2020 12; 78(6):783-785. doi:
10.1016/j.eururo.2020.08.007. [PMID: 32938569] - Fabian Hofmann, Eu Chang Hwang, Thomas Bl Lam, Axel Bex, Yuhong Yuan, Lorenzo So Marconi, Börje Ljungberg. Targeted therapy for metastatic renal cell carcinoma.
The Cochrane database of systematic reviews.
2020 10; 10(?):CD012796. doi:
10.1002/14651858.cd012796.pub2. [PMID: 33058158] - Allen Jacob, Jaret Shook, Thomas E Hutson. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Future oncology (London, England).
2020 Oct; 16(28):2147-2164. doi:
10.2217/fon-2020-0443. [PMID: 32692256] - S Vázquez Estévez, U Anido, M Lázaro, O Fernández, N Fernández Núñez, N de Dios Álvarez, V Varela, B Campos Balea, S Agraso, M C Areses, L Iglesias, M Blanco, S Maciá, L M Anton Aparicio. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2020 Sep; 22(9):1565-1579. doi:
10.1007/s12094-020-02300-2. [PMID: 32062835] - Kevin M Wright. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Oncology (Williston Park, N.Y.).
2020 Jul; 34(7):257. doi:
NULL. [PMID: 32674211] - Carrie Printz. Experimental drug for kidney cancer may work better than food and drug administration-Approved treatment.
Cancer.
2020 06; 126(11):2509. doi:
10.1002/cncr.32953. [PMID: 32396696] - Jing Wang, Maaike A C Bruin, Changpei Gan, Maria C Lebre, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
International journal of pharmaceutics.
2020 May; 581(?):119277. doi:
10.1016/j.ijpharm.2020.119277. [PMID: 32234426] - Stefano Fogli, Camillo Porta, Marzia Del Re, Stefania Crucitta, Giulia Gianfilippo, Romano Danesi, Brian I Rini, Manuela Schmidinger. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Cancer treatment reviews.
2020 Mar; 84(?):101966. doi:
10.1016/j.ctrv.2020.101966. [PMID: 32044644] - Christos Fountzilas, Medhavi Gupta, Sunyoung Lee, Smitha Krishnamurthi, Bassam Estfan, Katy Wang, Kristopher Attwood, John Wilton, Robert Bies, Wiam Bshara, Renuka Iyer. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
British journal of cancer.
2020 03; 122(7):963-970. doi:
10.1038/s41416-020-0737-6. [PMID: 32037403] - Brian I Rini, Sumanta K Pal, Bernard J Escudier, Michael B Atkins, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael N Needle, David F McDermott. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
The Lancet. Oncology.
2020 01; 21(1):95-104. doi:
10.1016/s1470-2045(19)30735-1. [PMID: 31810797] - Axel Bex. Sequencing therapy for advanced renal cancer.
The Lancet. Oncology.
2020 01; 21(1):9-11. doi:
10.1016/s1470-2045(19)30781-8. [PMID: 31810798] - M A C Bruin, H Rosing, L Lucas, J Wang, A D R Huitema, A H Schinkel, J H Beijnen. Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Sep; 1125(?):121723. doi:
10.1016/j.jchromb.2019.121723. [PMID: 31352204] - Giuseppe Procopio, Sandro Pignata, Amelia Altavilla, Laura Attademo, Delia De Lisi, Elena Verzoni, Ugo De Giorgi, Daniele Santini. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Future oncology (London, England).
2019 Aug; 15(22):2657-2666. doi:
10.2217/fon-2018-0857. [PMID: 31339065] - Bernard Escudier, Camillo Porta, Tim Eisen, Jonathan Belsey, Damilola Gibson, Jonathan Morgan, Robert Motzer. The role of tivozanib in advanced renal cell carcinoma therapy.
Expert review of anticancer therapy.
2018 11; 18(11):1113-1124. doi:
10.1080/14737140.2018.1508348. [PMID: 30084668] - Matteo Santoni, Francesco Massari, Francesco Piva, Francesco Carrozza, Vincenzo Di Nunno, Alessia Cimadamore, Angelo Martignetti, Rodolfo Montironi, Nicola Battelli. Tivozanib for the treatment of renal cell carcinoma.
Expert opinion on pharmacotherapy.
2018 Jun; 19(9):1021-1025. doi:
10.1080/14656566.2018.1480722. [PMID: 29851529] - Ana M Molina, Thomas E Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N Sternberg, Robert Motzer, Tim Eisen. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
European journal of cancer (Oxford, England : 1990).
2018 05; 94(?):87-94. doi:
10.1016/j.ejca.2018.02.009. [PMID: 29547835] - Esther S Kim. Tivozanib: First Global Approval.
Drugs.
2017 Nov; 77(17):1917-1923. doi:
10.1007/s40265-017-0825-y. [PMID: 28971328] - L Saes, F A L M Eskens. Tivozanib: a new treatment option for renal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998).
2017 Nov; 53(11):609-618. doi:
10.1358/dot.2017.53.11.2724804. [PMID: 29451277] - Sergio Fernández-Pello, Fabian Hofmann, Rana Tahbaz, Lorenzo Marconi, Thomas B Lam, Laurence Albiges, Karim Bensalah, Steven E Canfield, Saeed Dabestani, Rachel H Giles, Milan Hora, Markus A Kuczyk, Axel S Merseburger, Thomas Powles, Michael Staehler, Alessandro Volpe, Börje Ljungberg, Axel Bex. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
European urology.
2017 03; 71(3):426-436. doi:
10.1016/j.eururo.2016.11.020. [PMID: 27939075] - Jayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, Yangming Ou, Kyrre E Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, John G Evans, Jorg Dietrich, Andrew S Chi, Patrick Y Wen, Stephen Stufflebeam, Bruce Rosen, Dan G Duda, Rakesh K Jain, Tracy T Batchelor, Elizabeth R Gerstner. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Journal of neuro-oncology.
2017 02; 131(3):603-610. doi:
10.1007/s11060-016-2332-5. [PMID: 27853960] - Shweta Takyar, Jose Diaz, Manu Sehgal, Francisco Sapunar, Hardev Pandha. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Anti-cancer drugs.
2016 Jun; 27(5):383-97. doi:
10.1097/cad.0000000000000335. [PMID: 26886011] - S K Kang, A Volodarskiy, E L Ohmann, A V Balar, S Bangalore. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Clinical oncology (Royal College of Radiologists (Great Britain)).
2016 May; 28(5):334-41. doi:
10.1016/j.clon.2015.12.004. [PMID: 26723100] - Shiwei Guo, Xuehai Pang, Lingling Peng, Miao Zhan, Lei Fan, Yu Gong, Fanyuan Kang, Yuanwei Chen. Design, synthesis and biological evaluation of deuterated Tivozanib for improving pharmacokinetic properties.
Bioorganic & medicinal chemistry letters.
2015 Jun; 25(11):2425-8. doi:
10.1016/j.bmcl.2015.03.088. [PMID: 25908516] - K R Johnson, W Liauw, M N D Lassere. Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.
Annals of oncology : official journal of the European Society for Medical Oncology.
2015 Mar; 26(3):485-96. doi:
10.1093/annonc/mdu267. [PMID: 25057168] - Amikumar Mehta, Guru Sonpavde, Bernard Escudier. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Future oncology (London, England).
2014 Aug; 10(11):1819-26. doi:
10.2217/fon.14.120. [PMID: 25325825] - Robert A Figlin. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
Immunotherapy.
2014; 6(3):261-8. doi:
10.2217/imt.13.168. [PMID: 24354908] - Robert J Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y Alekseev, Cora N Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E Hutson. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013 Oct; 31(30):3791-9. doi:
10.1200/jco.2012.47.4940. [PMID: 24019545] - Marc B Garnick. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013 Oct; 31(30):3746-8. doi:
10.1200/jco.2013.51.4869. [PMID: 24019543] - M N Fishman, S Srinivas, R J Hauke, R J Amato, B Esteves, M M Cotreau, A L Strahs, W J Slichenmyer, P Bhargava, F F Kabbinavar. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
European journal of cancer (Oxford, England : 1990).
2013 Sep; 49(13):2841-50. doi:
10.1016/j.ejca.2013.04.019. [PMID: 23726267] - Masashi Niwakawa, Raizo Yamaguchi, Yusuke Onozawa, Hirofumi Yasui, Keisei Taku, Tateaki Naito, Shiro Akinaga, Narikazu Boku, Nobuyuki Yamamoto. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Cancer science.
2013 Aug; 104(8):1039-44. doi:
10.1111/cas.12197. [PMID: 23679664] - Han Hsi Wong, Tim Eisen. Tivozanib for the treatment of metastatic renal cancer.
Expert review of anticancer therapy.
2013 Jun; 13(6):649-60. doi:
10.1586/era.13.40. [PMID: 23773100] - E M Berge, D W Bowles, T W Flaig, E T Lam, A Jimeno. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Drugs of today (Barcelona, Spain : 1998).
2013 May; 49(5):303-15. doi:
10.1358/dot.2013.49.5.1960218. [PMID: 23724410] - C Lance Cowey. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Drug design, development and therapy.
2013; 7(?):519-27. doi:
10.2147/dddt.s31442. [PMID: 23818763] - Robert Figlin. Tivozanib in renal cell carcinoma.
Clinical advances in hematology & oncology : H&O.
2013 Jan; 11(1):43-5. doi:
NULL. [PMID: 23416862] - Brigitte C M Haberkorn, Ferry A L M Eskens. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
Future oncology (London, England).
2013 Jan; 9(1):13-20. doi:
10.2217/fon.12.167. [PMID: 23252559] - Michele McTigue, Brion William Murray, Jeffrey H Chen, Ya-Li Deng, James Solowiej, Robert S Kania. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
Proceedings of the National Academy of Sciences of the United States of America.
2012 Nov; 109(45):18281-9. doi:
10.1073/pnas.1207759109. [PMID: 22988103] - Dmitry A Nosov, Brooke Esteves, Oleg N Lipatov, Alexei A Lyulko, A A Anischenko, Raju T Chacko, Dinesh C Doval, Andrew Strahs, William J Slichenmyer, Pankaj Bhargava. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012 May; 30(14):1678-85. doi:
10.1200/jco.2011.35.3524. [PMID: 22493422] - Shilpa Gupta, Mayer Fishman. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Expert opinion on pharmacotherapy.
2011 Dec; 12(18):2915-22. doi:
10.1517/14656566.2011.636032. [PMID: 22098229] - Ferry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011 Nov; 17(22):7156-63. doi:
10.1158/1078-0432.ccr-11-0411. [PMID: 21976547] - NULL. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
Nature reviews. Drug discovery.
2011 Apr; 10(4):248. doi:
10.1038/nrd3420. [PMID: 21455225]
